Starvation SP, Mullighan CG. Acute lymphoblastic leukemia in kids. N. Engl J Med. 2015;373:1541–52.
Inaba H, Pui CH. Advances within the analysis and remedy of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10:1926.
Ribeiro RC, Pui CH. Saving the children-improving childhood most cancers remedy in creating international locations. N. Engl J Med. 2005;352:2158–60.
Starvation SP, Sung L, Howard SC. Remedy methods and regimens of graduated depth for childhood acute lymphoblastic leukemia in low-income international locations: a proposal. Pediatr Blood Most cancers. 2009;52:559–65.
Yeoh AE, Tan D, Li CK, Hori H, Tse E, Pui CH, Asian Oncology Summitt 2013. Administration of grownup and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified tips from the Asian Oncology Summit 2013. Lancet Oncol. 2013;14:e508–23.
Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biological options of 5202 sufferers with acute lymphoblastic leukemia enrolled within the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98:1702–10.
Cree IA. The WHO classification of haematolymphoid tumours. Leukemia. 2022;36:1701–2.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The fifth version of the World Well being Group classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Well being Group classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
Wang J, Bhakta N, Ayer Miller V, Revsine M, Litzow MR, Paietta E, et al. Acute leukemia classification utilizing transcriptional profiles from low-cost nanopore mRNA sequencing. JCO Summary Oncol. 2022;6:e2100326.
Lee SHR, Antillon-Klussmann F, Pei D, Yang W, Roberts KG, Li Z, et al. Affiliation of genetic ancestry with the molecular subtypes and prognosis of childhood acute lymphoblastic leukemia. JAMA Oncol. 2022;8:354–63.
Lee SHR, Ashcraft E, Yang W, Roberts KG, Gocho Y, Rowland L, et al. Prognostic and pharmacotypic heterogeneity of hyperdiploidy in childhood ALL. J Clin Oncol. 2023;41:5422–32.
Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, et al. Scientific significance of novel subtypes of acute lymphoblastic leukemia within the context of minimal residual disease-directed remedy. Blood Most cancers Discov. 2021;2:326–37.
Pedrosa F, Coustan-Smith E, Zhou Y, Cheng C, Pedrosa A, Lins MM, et al. Lowered-dose depth remedy for pediatric lymphoblastic leukemia: long-term outcomes of the Recife RELLA05 pilot research. Blood. 2020;135:1458–66.
Sidhom I, Shaaban Ok, Youssef SH, Ali N, Gohar S, Rashed WM, et al. Lowered-intensity remedy for pediatric lymphoblastic leukemia: impression of residual illness early in remission induction. Blood. 2021;137:20–28.
Cecconello DK, Werlang ICR, Alegretti AP, Hahn MC, de Magalhaes MR, Battistel AP, et al. Monitoring asparaginase exercise in middle-income international locations. Lancet Oncol. 2018;19:1149–50.
Barr RD, Furneaux R, Margottini L, Eden TOB. The worldwide scandal of faulty asparaginase: a blight on kids with most cancers. Pediatr Blood Most cancers. 2023;70:e30403.
Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, et al. Prednisone response is the strongest predictor of remedy consequence in toddler acute lymphoblastic leukemia. Blood. 1999;94:1209–17.
Ito C, Evans WE, McNinch L, Coustan-Smith E, Mahmoud H, Pui CH, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14:2370–6.
Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Variations in cerebrospinal fluid penetration of corticosteroids: potential relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5:202–7.
Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11:1096–106.
Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, et al. Dexamethasone vs prednisone in induction remedy of pediatric ALL: outcomes of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127:2101–12.
Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston Ok, et al. Dexamethasone versus prednisone and each day oral versus weekly intravenous mercaptopurine for sufferers with standard-risk acute lymphoblastic leukemia: a report from the Kids’s Most cancers Group. Blood. 2003;101:3809–17.
Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Medical Analysis Council Childhood Leukaemia Working Social gathering. Good thing about dexamethasone in contrast with prednisolone for childhood acute lymphoblastic leukaemia: outcomes of the UK Medical Analysis Council ALL97 randomized trial. Br J Haematol. 2005;129:734–45.
Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, et al. Substituting dexamethasone for prednisone complicates remission induction in kids with acute lymphoblastic leukemia. Most cancers. 2000;88:1964–9.
Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A, et al. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) had been equally efficient as induction remedy for childhood acute lymphoblastic leukemia within the EORTC CLG 58951 randomized trial. Haematologica. 2014;99:1220–7.
Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, et al. No benefit of dexamethasone over prednisolone for the result of standard- and intermediate-risk childhood acute lymphoblastic leukemia within the Tokyo Kids’s Most cancers Research Group L95-14 protocol. J Clin Oncol. 2005;23:6489–98.
Vrooman LM, Stevenson KE, Supko JG, O’Brien J, Dahlberg SE, Asselin BL, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase every enhance consequence of youngsters and adolescents with newly identified acute lymphoblastic leukemia: outcomes from a randomized study-Dana-Farber Most cancers Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31:1202–10.
Henze G, Langermann HJ, Ritter J, Schellong G, Riehm H. Remedy technique for various danger teams in childhood acute lymphoblastic leukemia: a report from the BFM research group. Haematol Blood Transfus. 1981;26:87–93.
Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Möricke A, et al. Late MRD response determines relapse danger total and in subsets of childhood T-cell ALL: outcomes of the AIEOP-BFM-ALL 2000 research. Blood. 2011;118:2077–84.
Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Möricke A, et al. Molecular response to remedy redefines all prognostic components in kids and adolescents with B-cell precursor acute lymphoblastic leukemia: leads to 3184 sufferers of the AIEOP-BFM ALL 2000 research. Blood. 2010;115:3206–14.
Patrick Ok, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, et al. Consequence for youngsters and younger individuals with early T-cell precursor acute lymphoblastic leukaemia handled on a recent protocol, UKALL 2003. Br J Haematol. 2014;166:421–4.
Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, et al. Early T-cell precursor acute lymphoblastic leukaemia in kids handled in AIEOP centres with AIEOP-BFM protocols: a retrospective evaluation. Lancet Haematol. 2016;3:e80–6.
Wooden B, Devidas M, Summers RJ, Chen Z, Asselin BL, Rabin KR, et al. Prognostic significance of ETP phenotype and minimal residual illness in T-ALL: a Kids’s Oncology Group research. Blood. 2023;142:2069–78.
Campbell M, Kiss C, Zimmermann M, Riccheri C, Kowalczyk J, Felice MS, et al. Childhood Acute Lymphoblastic Leukemia: outcomes of the randomized acute lymphoblastic leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. J Clin Oncol. 2023;41:3499–511.
Freeman AI, Weinberg V, Brecher ML, Jones B, Glicksman AS, Sinks LF, et al. Comparability of intermediate-dose methotrexate with cranial irradiation for the post-induction remedy of acute lymphocytic leukemia in kids. N. Engl J Med. 1983;308:477–84.
Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Lengthy-term outcomes of 5 consecutive trials in childhood acute lymphoblastic leukemia carried out by the ALL-BFM research group from 1981 to 2000. Leukemia. 2010;24:265–84.
Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia sufferers. Outcomes and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122–33.
Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone and high-dose methotrexate enhance consequence for youngsters and younger adults with high-risk B-acute lymphoblastic leukemia: a report from Kids’s Oncology Group research AALL0232. J Clin Oncol. 2016;34:2380–8.
Winter SS, Dunsmore KP, Devidas M, Wooden BL, Esiashvili N, Chen Z, et al. Improved survival for youngsters and younger adults with T-lineage acute lymphoblastic leukemia: outcomes from the Kids’s Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018;36:2926–34.
Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Stopping and managing toxicities of high-dose methotrexate. Oncologist. 2016;21:1471–82.
Matloub Y, Bostrom BC, Starvation SP, Stork LC, Angiolillo A, Sather H, et al. Escalating intravenous methotrexate improves event-free survival in kids with standard-risk acute lymphoblastic leukemia: a report from the Kids’s Oncology Group. Blood. 2011;118:243–51.
Holland JF, Glidewell O. Oncologists’ reply: survival expectancy in acute lymphocytic leukemia. N. Engl J Med. 1972;287:769–77.
Aur RJ, Simone J, Hustu HO, Walters T, Borella L, Pratt C, et al. Central nervous system remedy and mixture chemotherapy of childhood lymphocytic leukemia. Blood. 1971;37:272–81.
Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, et al. Cumulative incidence of secondary neoplasms as a primary occasion after childhood acute lymphoblastic leukemia. JAMA. 2007;297:1207–15.
Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia with out cranial irradiation. N. Engl J Med. 2009;360:2730–41.
Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bokkerink JP, Bruin MC, et al. Dexamethasone-based remedy for childhood acute lymphoblastic leukaemia: outcomes of the possible Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009;10:957–66.
Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, et al. Improved CNS management of childhood acute lymphoblastic leukemia with out cranial irradiation: St Jude Whole Remedy Research 16. J Clin Oncol. 2019;37:3377–91.
Dunsmore KP, Winter SS, Devidas M, Wooden BL, Esiashvili N, Chen Z, et al. Kids’s Oncology Group AALL0434: a section III randomized medical trial testing nelarabine in newly identified T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020;38:3282–93.
Vora A, Andreano A, Pui CH, Starvation SP, Schrappe M, Moericke A, et al. Affect of cranial radiotherapy on consequence in kids with acute lymphoblastic leukemia handled with modern remedy. J Clin Oncol. 2016;34:919–26.
Jacola LM, Krull KR, Pui CH, Pei D, Cheng C, Reddick WE, et al. Longitudinal evaluation of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia handled on a recent chemotherapy protocol. J Clin Oncol. 2016;34:1239–47.
Jacola LM, Conklin HM, Krull KR, Pei D, Cheng C, Reddick WE, et al. The impression of intensified CNS-directed remedy on neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia handled with out cranial irradiation. J Clin Oncol. 2022;40:4218–27.
Gajjar A, Harrison PL, Sandlund JT, Rivera GK, Ribeiro RC, Rubnitz JE, et al. Traumatic lumbar puncture at analysis adversely impacts consequence in childhood acute lymphoblastic leukemia. Blood. 2000;96:3381–4.
Howard SC, Gajjar AJ, Cheng C, Kritchevsky SB, Somes GW, Harrison PL, et al. Danger components for traumatic and bloody lumbar puncture in kids with acute lymphoblastic leukemia. JAMA. 2002;288:2001–7.
Liu HC, Yeh TC, Hou JY, Chen KH, Huang TH, Chang CY, et al. Triple intrathecal remedy alone with omission of cranial radiation in kids with acute lymphoblastic leukemia. J Clin Oncol. 2014;32:1825–9.
Tang J, Yu J, Cai J, Zhang L, Hu S, Gao J, et al. Prognostic components for CNS management in kids with acute lymphoblastic leukemia handled with out cranial irradiation. Blood. 2021;138:331–43.
Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, et al. Intrathecal triple remedy decreases central nervous system relapse however fails to enhance event-free survival when put next with intrathecal methotrexate: outcomes of the Kids’s Most cancers Group (CCG) 1952 research for standard-risk acute lymphoblastic leukemia, reported by the Kids’s Oncology Group. Blood. 2006;108:1165–73.
Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, et al. Impression of intrathecal triple remedy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: Kids’s Oncology Group research AALL1131. J Clin Oncol. 2020;38:2628–38.
Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, et al. Profitable remedy discount and intensification for childhood acute lymphoblastic leukemia primarily based on minimal residual illness monitoring: research ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34:2591–601.
Ariffin H, Chiew EKH, Oh BLZ, Lee SHR, Lim EH, Kham SKY, et al. Anthracycline-free protocol for favorable-risk childhood ALL: a noninferiority comparability between Malaysia-Singapore ALL 2003 and ALL 2010 research. J Clin Oncol. 2023;41:3642–51.
Pieters R, de Groot-Kruseman H, Fiocco M, Verwer F, Van Overveld M, Sonneveld E, et al. Improved consequence for ALL by prolonging remedy for IKZF1 deletion and lowering remedy for different danger teams. J Clin Oncol. 2023;41:4130–42.
Schrappe M, Bleckmann Ok, Zimmermann M, Biondi A, Möricke A, Locatelli F, et al. Lowered-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia outlined by undetectable minimal residual illness: outcomes of a world randomized trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2018;36:244–53.
Teachey DT, Starvation SP, Loh ML. Optimizing remedy within the fashionable age: variations in size of upkeep remedy in acute lymphoblastic leukemia. Blood. 2021;137:168–77.
Childhood ALL Collaborative Group. Period and depth of upkeep chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised kids. Lancet. 1996;347:1783–8.
Kato M, Ishimaru S, Seki M, Yoshida Ok, Shiraishi Y, Chiba Ok, et al. Lengthy-term consequence of 6-month upkeep chemotherapy for acute lymphoblastic leukemia in kids. Leukemia. 2017;31:580–4.
Eden T, Pieters R, Richards S, Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). Systematic evaluate of the addition of vincristine plus steroid pulses in upkeep remedy for childhood acute lymphoblastic leukaemia – a person affected person knowledge meta-analysis involving 5,659 kids. Br J Haematol. 2010;149:722–33.
Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Glorious outcomes with decreased frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: outcomes from Kids’s Oncology Group AALL0932. J Clin Oncol. 2021;39:1437–47.
Yang W, Cai J, Shen S, Gao J, Yu J, Hu S, et al. Pulse remedy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, section 3, non-inferiority trial. Lancet Oncol. 2021;22:1322–32.
Guolla L, Breitbart S, Foroutan F, Thabane L, Loh ML, Teachey DT, et al. Impression of vincristine-steroid pulses in upkeep for B-cell pediatric ALL: a scientific evaluate and meta-analysis. Blood. 2023;141:2944–54.
Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR, et al. Nonadherence to oral mercaptopurine and danger of relapse in Hispanic and non-Hispanic white kids with acute lymphoblastic leukemia: a report from the youngsters’s oncology group. J Clin Oncol. 2012;30:2094–101.
Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, et al. Scientific pharmacogenetics implementation consortium guideline for thiopurine dosing primarily based on TPMT and NUDT15 genotypes: 2018 Replace. Clin Pharm Ther. 2019;105:1095–105.
Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a kids’s oncology group research. J Clin Oncol. 2009;27:5175–81.
Umeh CA, Garcia-Gonzalez P, Tremblay D, Laing R. The survival of sufferers enrolled in a worldwide direct-to-patient most cancers drugs donation program: the Glivec Worldwide Affected person Help Program (GIPAP). EClinicalMedicine. 2020;19:100257.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax together with chemotherapy in sufferers with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Most cancers Discov. 2021;11:1440–53.
Teachey DT, Devidas M, Wooden BL, Chen Z, Hayashi RJ, Hermiston ML, et al. Kids’s Oncology Group trial AALL1231: a section III medical trial testing bortezomib in newly identified T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2022;40:2106–18.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920–4.
Lee SHR, Yang W, Gocho Y, John A, Rowland L, Sensible B, et al. Pharmacotypes throughout the genomic panorama of pediatric acute lymphoblastic leukemia and impression on remedy response. Nat Med. 2023;29:170–9.
Jabbour E, Quick NJ, Senapati J, Jain N, Huang X, Daver N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or with out blinatumomab, within the subgroup of older sufferers with newly identified Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term outcomes of an open-label section 2 trial. Lancet Haematol. 2023;10:e433–44.
Jabbour E, Haddad FG, Quick NJ, Kantarjian H. Remedy of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-from intensive chemotherapy mixtures to chemotherapy-free regimens: a evaluate. JAMA Oncol. 2022;8:1340–8.
Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Impact of postreinduction remedy consolidation with blinatumomab vs chemotherapy on disease-free survival in kids, adolescents, and younger adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized medical trial. JAMA. 2021;325:833–42.
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Impact of blinatumomab vs chemotherapy on event-free survival amongst kids with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized medical trial. JAMA. 2021;325:843–54.
Hogan LE, Brown PA, Ji L, Xu X, Devidas M, Bhatla T, et al. Kids’s Oncology Group AALL1331: section III trial of blinatumomab in kids, adolescents, and younger adults with low-risk B-cell ALL in first relapse. J Clin Oncol. 2023;41:4118–29.
van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom Ok, et al. Blinatumomab added to chemotherapy in toddler lymphoblastic leukemia. N. Engl J Med. 2023;388:1572–81.
Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in kids with Down syndrome: a retrospective evaluation from the Ponte di Legno research group. Blood. 2014;123:70–77.
Verma A, Lupo PJ, Shah NN, Hitzler J, Rabin KR. Administration of down syndrome-associated leukemias: a evaluate. JAMA Oncol. 2023;9:1283–90.
Sora F, Annunziata M, Laurenti L, Giammarco S, Chiusolo P, Innocenti I, et al. Blinatumomab as a profitable and protected remedy in Down syndrome sufferers with relapsed/refractory B-precursor acute lymphoblastic leukaemia: case stories and literature evaluate. Pediatr Blood Most cancers. 2021;68:e29044.
Duffy C, Santana V, Inaba H, Jeha S, Pauley J, Sniderman L, et al. Evaluating blinatumomab implementation in low- and middle-income international locations: a research protocol. Implement Sci Commun. 2022;3:62.
Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Rifón Roca JJ, Cassaday RD, et al. Single agent subcutaneous blinatumomab for superior acute lymphoblastic leukemia. Am J Hematol. 2024;99:586–95.
Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year replace of tisagenlecleucel in pediatric and younger grownup sufferers with relapsed/refractory acute lymphoblastic leukemia within the ELIANA trial. J Clin Oncol. 2023;41:1664–9.
Palani HK, Arunachalam AK, Yasar M, Venkatraman A, Kulkarni U, Lionel SA, et al. Decentralized manufacturing of anti CD19 CAR-T cells utilizing CliniMACS Prodigy®: real-world expertise and value evaluation in India. Bone Marrow Transpl. 2023;58:160–7.
Bustamante-Ogando JC, Hernández-López A, Galván-Díaz C, Rivera-Luna R, Fuentes-Bustos HE, Meneses-Acosta A, Olaya-Vargas A. Childhood leukemias in Mexico: in direction of implementing CAR-T cell remedy packages. Entrance Oncol. 2023;13:1304805.
Tang JY, Pui CH. The worldwide collaboration to avoid wasting kids with most cancers. JAMA Oncol. 2021;7:499–500.
Burki TK. WHO and St Jude Kids’s Analysis Hospital announce childhood most cancers medicines initiative. Lancet Oncol. 2022;23:e17.
Metzger ML, Howard SC, Fu LC, Pena A, Stefan R, Hancock ML, et al. Consequence of childhood acute lymphoblastic leukaemia in resource-poor international locations. Lancet. 2003;362:706–8.
Alam A, Kumar A. Prevalence, predictors, causes of remedy refusal and abandonment in kids with acute lymphoblastic leukaemia over 18 years in North India. Remedy section affecting components: A step in direction of higher focussed counselling. Most cancers Epidemiol. 2018;57:53–59.
Howard SC, Davidson A, Luna-Fineman S, Israels T, Chantada G, Lam CG, et al. A framework to develop tailored remedy regimens to handle pediatric most cancers in low- and middle-income international locations: the Pediatric Oncology in Growing International locations (PODC) Committee of the Worldwide Pediatric Oncology Society (SIOP). Pediatr Blood Most cancers. 2017;64:e26879.
Frech S, Morton Doherty R, Lesmes Duque MC, Ramirez O, Pomata A, Samudio A, et al. C/Can metropolis engagement course of: an implementation framework for strengthening most cancers care in cities in low- and middle-income international locations. JCO Glob Oncol. 2021;7:901–16.
Atun R, Bhakta N, Denburg A, Frazier AL, Friedrich P, Gupta S, et al. Sustainable care for youngsters with most cancers: a Lancet Oncology Fee. Lancet Oncol. 2020;21:e185–224.
Rodriguez-Galindo C, Friedrich P, Alcasabas P, Antillon F, Banavali S, Castillo L, et al. Towards the treatment of all kids with most cancers via collaborative efforts: pediatric oncology as a worldwide problem. J Clin Oncol. 2015;33:3065–73.
Ortiz R, Vasquez L, Giri B, Kapambwe S, Dille I, Mahmoud L, et al. Growing and sustaining high-quality care for youngsters with most cancers: the WHO International Initiative for Childhood Most cancers. Rev Panam Salud Publica. 2023;47:e164.
Maloney KW, Devidas M, Wang C, Mattano LA, Friedmann AM, Buckley P, et al. Consequence in kids with standard-risk B-cell acute lymphoblastic leukemia: outcomes of Kids’s Oncology Group trial AALL0331. J Clin Oncol. 2020;38:602–12.
Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, et al. Outcomes of NOPHO ALL2008 remedy for sufferers aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606–15.
Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Remedy discount for youngsters and younger adults with low-risk acute lymphoblastic leukaemia outlined by minimal residual illness (UKALL 2003): a randomised managed trial. Lancet Oncol. 2013;14:199–209.
Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, et al. Augmented post-remission remedy for a minimal residual disease-defined high-risk subgroup of youngsters and younger individuals with medical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised managed trial. Lancet Oncol. 2014;15:809–18.
